A recent study indicates that the number of individuals without diabetes but classified as overweight or obese who initiated treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) in the US has surged, from approximately 21,000 in 2019 to over 174,000 by 2023—representing an increase of more than 700%.1 Researchers at the University of Pennsylvania, in collaboration with Cedars-Sinai Medical Center in Los Angeles, analyzed data through TriNetX, a network containing health

— Lack of Institutional Support and Knowledge rank as Key Factors A recent systematic review of 283 studies has determined that a lack of institutional backing remains the top reason clinicians hesitate to intervene in addiction cases, as highlighted by the findings. In their analysis, Wilson Compton, MD, MPE, deputy director of the National Institute on Drug Abuse (NIDA), and his colleagues reported in JAMA Network Open that 81.2% of the reviewed articles cited the institutional environment as